Liver Cancer Drug Watch
Compounds in Development for Liver Cancer
Updated January 2025
Drug Name |
Mechanism |
Company |
Company Website |
USA Status |
Clinical Trial Website |
||||
|
Nexavar (Sorafenib) |
VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor |
Bayer |
Approved |
N.A. | |||||
|
Keytruda(Pembrolizumab) |
PD-1 checkpoint inhibitor |
Merck |
Approved for use after treatment with sorafenib (Nexavar) | N.A. | |||||
| Opdivo (Nivolumab) + Yervoy (Ipilimumab) |
Opdivo: PD-1 checkpoint inhibitor Yervoy: CTLA-4-blocking antibody |
Bristol-Myers Squibb | bmsclinicaltrials.com | Approved for combination use after treatment with sorafenib (Nexavar) | N.A. | ||||
|
Stivarga (Regorafenib) |
VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor |
Bayer |
Approved |
N.A. |
|||||
|
Opdivo (Nivolumab) |
PD1 inhibitor |
Bristol Myers-Squibb |
Approved |
N.A. | |||||
|
Lenvima (Lenvatinib) |
VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor |
Eisai |
Approved |
N.A. | |||||
|
Cabometyx (Cabozantinib) |
VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor |
Exelixis |
Approved |
N.A. | |||||
|
Tecentriq (Atezolizumab) + Avastin (Bevacizumab) |
PD-L1 monoclonal antibody/VEGFA inhibitor |
Genentech |
Approved |
N.A. | |||||
|
Cyramza (Ramucirumab) |
VEGFR2 inhibitor |
Eli Lilly and Co. |
Approved |
N.A. | |||||
|
Imjudo (tremelimumab) |
CTLA-4 |
AstraZeneca |
Approved |
N.A. |
|||||
|
Imfinzi (Durvalumab) + Tremelimumab (imjudo) |
PD-L1/CTLA-4 monoclonal antibody |
AstraZeneca |
Approved |
N.A. |
|||||
|
Cabozantinib + Opdivo (Nivolumab) ± Yervoy (Ipilimumab) |
MET inhibitor, PD1 inhibitor, CTLA-4-blocking antibody |
Exelixis and Bristol-Myers Squibb |
Approved |
N.A. |
|||||
|
Atezolizumab + , Bevacizumab + or - Tiragolumab |
Roche |
Phase III | Clinical Trial
|
||||||
|
Atezolizumab + Multi-Kinase Inhibitor vs. Multi-Kinase Inhibitor (Cabozantinib or Lenvatinib) alone |
Roche |
Phase II |
|||||||
|
Atezolizumab + Bevacizumab or Atezolizumab alone |
Genentech |
gene.com | Phase II | ||||||
|
Combinations of Atezolizumab, Tiragolumab, Bevacizumab, Tobemstomig |
Roche |
Phase I/II | Clinical Trial | ||||||
|
Combinations of Atezolizumab, Tiragolumab, Bevacizumab, Tobemstomig, Tocilizumab, TPST-1120, ADG126 |
Roche |
Phase I/II | Clinical Trial | ||||||
|
Cabozantinib + Tecentriq (Atezolizumab) vs. Nexavar (Sorafenib) |
MET inhibitor + PD-L1 monoclonal antibody vs. Raf/Mek/Erk inhibitor |
Exelixis |
Phase III |
||||||
|
Toripalamib + Lenvatinib |
PD-1/VEGFR2, VEGFR3 antibody |
Shanghai Junshi Bioscience Co. | |||||||
|
Nexavar (Sorafenib), as adjuvant |
Raf, KIT, FLT, RET, VEGFR, PDGFR inhibitor |
Bayer |
Phase III |
Study completed |
|||||
|
Yiviva (YIV-906) + Sorafenib |
Botanical |
Yiviva Inc. |
Phase II |
||||||
|
MTL-CEBPA + Sorafenib |
CEBPA RNA Activator | MiNA Therapeutics | minatx.com | Phase II | Clinical Trial | ||||
|
Pembrolizumab + Nexavar (Sorafenib) |
PD-1/VEGFRs, C-KIT, PDGFRB, RAF inhibitor |
Roswell Park Cancer Institute and Merck Sharpe & Dohme Corp. |
Phase I/II |
||||||
|
Pembrolizumab + Lenvima (Lenvatinib) |
PD-1/VEGFR2, VEGFR3 antibody |
Eisai |
Phase III |
||||||
|
|
Eisai | lenvima.com | Phase III | Clinical Trial
|
||||
|
Cabozantinib + Opdivo (Nivolumab) |
MET inhibitor, VEGFRs/PD-1 antibody |
Exelixis and Bristol-Myers Squibb |
Phase II |
Study completed (before resection) Clinical Trial (with TACE) |
|||||
| ET140203 Artemis® T Cells | T-cell therapy | Eureka Therapeutics | eurekatherapeutics.com | Phase I/II |
Clinical Trial (ARYA-1) Clinical Trial (ARYA-2) |
||||
|
Stivarga (Regorafenib) + Pembrolizumab |
VEGFRs, FGFRs, C-KIT, PDGFRs, RAF/PD-1 antibody |
Bayer and Merck Sharpe & Dohme Corp. |
Phase II |
||||||
|
Tremelimumab (Imjudo), Durvalumab (Imfinzi) +/- Lenvatinib (Lenvima) + TACE |
PL-L1, CTLA4, VEGF |
AstraZeneca |
astrazeneca.com |
Phase III |
Clinical Trial | ||||
|
Durvalumab (Imfinzi) + Bevacizumab (Avastin) + TACE |
PL-L1, VEGF |
AstraZeneca |
Phase III | Clinical Trial | |||||
|
Durvalumab (Imfinzi) + Bevacizumab (Avastin) |
PL-L1, VEGF | AstraZeneca | astrazeneca.com | Phase III | Clinical Trial | ||||
|
Nivolumab + Relatlimab + Bevacizumab |
PD-1 small molecular inhibitor, LAG3 inhibitor, VEGF | BMS | bmsclinicaltrials.com | Phase I/II | Clinical Trial | ||||
|
Regorafenib + Pembrolizumab vs. TACE |
VEGFRs, FGFRs, C-KIT, PDGFRs, RAF/PD-1 antibody | Bayer | stivarga.com | Phase III | |||||
|
Pembrolizumab + Lenvatinib + Belzutifan |
PD-1 inhibitor, VEGF inhibitor, HIF-2α inhibitor | Merck | merckclinicaltrials.com | Phase II | |||||
|
Domvanalimab + Zimberelimab |
TIGIT inhibitor, PD-1 inhibitor | Arcus | arcusbio.com | Phase II | |||||
|
SIRT + Tremelimumab + Durvalumab |
NAD+-dependent deacetylases, CTLA-4 inhibitor, PD-1 inhibitor | Astrazeneca | astrazeneca.com | Phase I | |||||
|
AU409 |
Alters gene expression profile of liver cancer cells | Auransa | auransa.com | Phase I | |||||
| Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab | PD-1 inhibitor, VEGF inhibitor, CTLA-4 inhibitor | Bayer | bayer.com | Observational | |||||
| BAY3630942 | Monoclonal anti-body attached to tracer | Bayer | bayer.com | Phase I | |||||
| BST02 | Expansion of patient's TILs | BioSyngen | biosyngen.com | Phase I | |||||
| Nivolumab | PD-1 inhibitor |
Bristol-Myers Squibb
|
bmsclinicaltrials.com | Phase I/II | |||||
| Nivolumab or Sorafenib | PD-1 inhibitor, VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor |
Bristol-Myers Squibb
|
bmsclinicaltrials.com | Phase III | Clinical Trial | ||||
| LY2157299 | TGF-Beta inhibitor |
Eli Lilly
|
lilly.com | Phase I | Clinical Trial | ||||
| Pembrolizumab (MK-3475) | PD-1 inhibitor |
Merck
|
merckclinicaltrials.com | Phase III | Clinical Trial | ||||
| Trametinib + Sorafenib | MEK1/2 inhibitor, VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor | Moffitt Cancer Center | moffitt.org | Phase I | Clinical Trial | ||||
| MT-303 | GPC3 inhibitor | Myeloid Therapeutics | myeloidtx.com | Phase I | Clinical Trial |